Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.

Ann Hematol · 2021 · PMC7960595 · PMID 33641019

Europe PMC DOI

hedged sentence

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

did not reach statistical significancep =0.16not close (p > 0.1)

Although a higher OS rate was observed for the real-world IPS 3+ eBEACOPP patients compared to the IPS 3+ RATHL patients (100% vs 91.4%; HR 0.27), this did not reach statistical significance ( p =0.16) (Fig. 4c ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.